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Abstract MPS VI (mucopolysaccharidosis VI,
known as Maroteaux–Lamy syndrome) is a multi-
systemic inherited disease, resulting from a defi-
ciency of N-acetylgalactosamine-4-sulfatase, causing
accumulation of the glycosaminoglycan (GAG) der-
matan sulfate in all tissues. It is one of almost 50
lysosomal storage disorders. Ocular pathology is
common in patients with MPS VI, with complications
including ocular hypertension, progressive corneal
clouding, optic nerve swelling (or papilledema) often
associated with communicating hydrocephalus
(Ashworth et al., Eye 20(5), 553–563, 2006;
Goldberg et al., AJO 69(6), 969–975), and raised
intracranial pressure (ICP) progressing to atrophy
with loss of vision (Goodrich et al., Loss of vision in
MPS VI is a consequence of increased intracranial
pressure, 2002). This is the first case report of
reversed papilledema and improved visual acuity in
an 11-year-old MPS VI patient receiving galsulfase
(Naglazyme), an enzyme-replacement therapy
(ERT) of recombinant human arylsulfatase B
(rhASB) (Harmatz et al., J Pediatr 148(4), 533–539,
2006).
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Abbreviations
ERT Enzyme replacement therapy
MPS VI Mucopolysaccharidosis VI, known
as Maroteaux–Lamy syndrome
RhASB Recombinant human arylsulfatase B
MPS VI (Maroteaux–Lamy syndrome) is a multi-
systemic inherited disease, resulting from a deficiency
of N-acetylgalactosamine-4-sulfatase (arylsulfatase
B), causing accumulation of glycosaminoglycan
(GAG) dermatan sulfate in all tissues. Ocular patho-
logy is common in patients with MPS VI, with
complications including ocular hypertension, progres-
sive corneal clouding, optic nerve swelling and
atrophy, papilledema secondary to hydrocephalus,
glaucoma, and blindness.
The objective of this case report is to describe the first
report of a patient with MPS VI disease with resolution
of papilledema and improved vision subsequent to
enzyme-replacement therapy with recombinant human
arylsulfatase B (rhASB), galsulfase.
The patient, an 11-year-old Hispanic female, was
treated with rhASB in an open-label extension of a
24-week randomized double-blind study evaluating
the safety and efficacy of rhASB. At baseline, the
patient presented with characteristic features of MPS
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VI: short stature, coarse facies, large tongue, hepa-
tosplenomegaly, joint contractures, and mitral and
aortic regurgitation. Leukocyte pellet and fibroblast
cell analyses showed no detectable N-acetylgalactos-
amine-4-sulfatase activity. The patient received
placebo during the double-blind portion of the trial
and began rhASB during the open-label extension
study. She was followed for two years.
During baseline screening for a phase-three cli-
nical trial, the MPS VI patient presented with a
urinary glycosaminoglycan (GAG) level of 243 lg/
mg creatinine [1]. Ocular pathology included optic
atrophy, and moderate corneal clouding in both eyes,
with decreased visual acuity: right eye 20/60, left eye
20/400 (Table 1). Her ophthalmic condition wors-
ened and included papilledema while on placebo
concomitant with urinary GAG level increasing to
358 lg/mg creatinine, but both parameters rapidly
improved after switching to open-label extension and
commencing active drug at 1 mg/kg delivered by
weekly IV infusion from week 25. Papilledema had
largely resolved in both eyes, associated with a
recorded decrease of urinary GAG levels to 77 lg/mg
creatinine when monitored at week 36 of trial.
Resolution of papilledema was maintained with
weekly galsulfase treatment for two and a half years.
Visual acuity improved from 20/60 to 20/40 in her
right eye with best correction. Both corneas remained
moderately cloudy during the study. The left optic
nerve continued to be atrophic and vision got worse,
likely due to the severity of the damage, counting
fingers only at one meter. A second MPS VI patient
in the trial developed papilledema while on placebo,
and had to be treated for underlying hydrocephalus
with an emergency shunt procedure.
Discussion
Although galsulfase may not adequately cross the
blood–brain barrier [2], possible beneficial mecha-
nisms include relief of pressure around the optic nerve
by reducing dural thickening along the optic canal or
reducing scleral thickening at the disc. It is possible
that galsulfase ERT reduced ICP by working intravas-
cularly or relieving pressure around the brainstem. This
case study suggests that earlier galsulfase ERT may
prevent or decrease optic nerve swelling, atrophy, and
blindness in MPS VI patients, in the absence of
increased ICP. These findings suggest that MPS VI
patients who show acute vision changes or optic nerve
swelling, as evaluated by specialists in ophthalmology,
radiology, and neurosurgery, might benefit from ERT
with galsulfase, but further studies are necessary to
confirm this hypothesis. Galsulfase has been found to
have an adequate safety profile in clinical trials and is
approved by the FDA and EMEA.
This is the first case of papilledema resolution with
improved vision associated with rhASB therapy of
MPS VI. Early enzyme-replacement therapy may
prevent or decrease optic nerve atrophy resulting in
blindness in MPS VI patients.
Table 1 Ocular examination findings
Exam date VARb VALc CRd CLe Alignment ONPRf ONPLg
8/27/2003a 20/60 20/400 Cloudy Cloudy Extropia Negative Negative
2/5/2004 20/60 CFh @ 1 m Cloudy Cloudy Extropia Positive Positive
3/4/2004 20/60 CF @ 1 m Cloudy Cloudy Extropia Negative Negative
6/21/2005 20/50 CF @ 1 m Cloudy Cloudy Extropia Negative Negative
9/27/2006 20/40 CF @ 1 m Cloudy Cloudy Extropia Negative Negative
a 8/27/2003 was date of baseline reading
b VAR = visual acuity right
c VAL = visual acuity left
d CR = cornea right
e CL = cornea left
f ONPR = optical nerve papilledema right
g ONPL = optical nerve papilledema left
h CF @ 1 m = counting fingers at a distance of 1 m
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Note to editor: The procedures followed in this
clinical case were in accordance with the Institutional
Review Board (IRB) subjected to the United States
FDA’s IRB regulations, and the ethical standards of
the Declaration of Helsinki (1964) of the World
Medical Association (amended in 1975 and 1983).
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